Essam Ahmed Sheta

US Patent:

20060029574, Feb 9, 2006

Filed:

Aug 6, 2004

Appl. No.:

10/913296

Inventors:

Maher Albitar - Coto De Caza CA, US
Hagop Kantarjian - Bellaire TX, US
Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US

International Classification:

G01N 33/574

US Classification:

424093100, 435007230

Abstract:

The present invention provides methods and compositions for identifying cancer cells that are either sensitive or resistant to a particular anti-cancer therapy. Accordingly, the present invention allows for more accurate diagnosis, prognosis, and monitoring of a subject's condition. Furthermore, the ability to assess a subject's resistance or sensitivity to a particular treatment regimen will permit more informed treatment decisions to be made prior to beginning therapy. The present invention also overcomes deficiencies in the prior art concerning the treatment of cancers by providing methods and compositions for treating cancer and improving the effectiveness of other cancer therapies.

US Patent:

20060046276, Mar 2, 2006

Filed:

Sep 1, 2004

Appl. No.:

10/931333

Inventors:

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US

Assignee:

Power3 Medical Products, Inc. - The Woodlands TX

International Classification:

G01N 33/567
G01N 33/574

US Classification:

435007210, 435007230

Abstract:

The present invention is a biomarker for breast cancer, including early stage and precancerous conditions. Patients exhibiting reduced expression of acetyl-LDL receptor in a NAF sample collected from a breast that is below the 95% confidence limit of normals either have breast cancer are at high risk to develop breast cancer and should become the object of increased medical surveillance.

US Patent:

20060068452, Mar 30, 2006

Filed:

Jun 29, 2005

Appl. No.:

11/172219

Inventors:

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Melanie Black - The Woodlands TX, US
Chris Wilson - Spring TX, US
Helen Park - Huntsville TX, US

Assignee:

Power3 Medical Products, Inc. - The Woodlands TX

International Classification:

G01N 33/574
G06K 9/00

US Classification:

435007230, 382128000

Abstract:

The present invention is a method for determining protein expression profiles in disease or an altered biological state. The method is based on the use of two-dimensional (2D) gel electrophoresis where the gel images are assigned two different colors. The gels are then compared by an overlay procedure that allows for identification and quantification of unique proteins by determining which colors are detected in the superimposed images and the density of those colors.

US Patent:

20060115854, Jun 1, 2006

Filed:

Jan 19, 2005

Appl. No.:

11/038753

Inventors:

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Stanley Appel - Houston TX, US
Ericka Simpson - Pearland TX, US
Albert Yen - Pearland TX, US

Assignee:

Power3 Medical Products, Inc. - The Woodlands TX

International Classification:

A61K 38/17
G01N 33/53
C07K 14/705
C07K 16/28

US Classification:

435007100, 514002000, 530350000, 530388220

Abstract:

The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of an acetyl-LDL receptor related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

US Patent:

20060115855, Jun 1, 2006

Filed:

Jan 19, 2005

Appl. No.:

11/038754

Inventors:

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Stanley Appel - Houston TX, US
Ericka Simpson - Pearland TX, US
Albert Yen - Pearland TX, US

Assignee:

Power3 Medical Products, Inc. - The Woodlands TX

International Classification:

G01N 33/53
C07K 14/705
C07K 16/28

US Classification:

435007100, 530350000, 530388220

Abstract:

The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of the FK 506-binding protein 7, or prolylisomerase, as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

US Patent:

20060115856, Jun 1, 2006

Filed:

Jan 19, 2005

Appl. No.:

11/039005

Inventors:

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Stanley Appel - Houston TX, US
Ericka Simpson - Pearland TX, US
Albert Yen - Pearland TX, US

Assignee:

Power3 Medical Products, Inc. - The Woodlands TX

International Classification:

G01N 33/53
C12N 9/22
C07K 16/40

US Classification:

435007100, 435199000, 530388260

Abstract:

The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of an 2′-5′-oligoadenylate synthetase like protein (p59 OASL) related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

US Patent:

20060115867, Jun 1, 2006

Filed:

Jan 19, 2005

Appl. No.:

11/039600

Inventors:

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Stanley Appel - Houston TX, US
Ericka Simpson - Pearland TX, US
Albert Yen - Pearland TX, US

Assignee:

Power3 Medical Products, Inc. - The Woodlands TX

International Classification:

C07K 14/705
C07K 16/28
G01N 33/53
G01N 33/537
G01N 33/543

US Classification:

435007930, 530350000, 530388220

Abstract:

The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of a tripartite motif protein TRIM5 isoform gamma related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

US Patent:

20060278532, Dec 14, 2006

Filed:

Apr 26, 2006

Appl. No.:

11/411659

Inventors:

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Stanley Appel - Houston TX, US
Jennifer Bryson - The Woodlands TX, US
Lemuel Moye - Houston TX, US
Albert Yen - Houston TX, US
Brian Folsom - Chaska MN, US
Miguel Mosqueda - Willis TX, US

Assignee:

Power3 Medical Products, Inc. - The Woodlands TX

International Classification:

G01N 27/26

US Classification:

204601000

Abstract:

The present invention is an assay for determining if a patient has a neuromuscular disease. The method comprises collecting a biological sample from a patient, separating the proteins present in the biological sample, quantitating a panel of proteins by proteomic techniques, analyzing the quantity of the protein panel using biostatistics, and determining whether or not the patient has a neuromuscular disease based on the statistical analysis of the results.